Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status

详细信息    查看全文

• 作者：De-lan Li ; Xin-ru Chen ; Shu-xiang Ma and Li-kun Chen
• 刊名：Thoracic Cancer
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：7
• 期：5
• 页码：619-622
• 全文大小：247K
• ISSN：1759-7714

文摘

Identification of the anaplastic lymphoma kinase (ALK) gene has refined the classification of non-small cell lung cancer (NSCLC) and promoted research on molecularly targeted drugs such as crizotinib, an ALK inhibitor with good efficacy, in ALK-rearranged NSCLC. At present, few studies have reported the efficacy of crizotinib in patients with ALK-rearranged NSCLC with brain metastases. In a patient with NSCLC harboring ALK-rearrangement who had brain metastases and poor performance status (PS), we obtained a durable response with crizotinib administered following multi-line chemotherapy regimens.